{
    "2018-01-26": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors",
                "features": {
                    "keywords": [
                        "FDA Approval",
                        "Lutathera",
                        "Gastroenteropancreatic Neuroendocrine Tumors"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Stocks With Rising Relative Strength: Novartis",
                "features": {
                    "keywords": [
                        "Rising Relative Strength",
                        "Novartis"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Novartis Gets Spark Therapeutics' Luxterna License Outside US",
                "features": {
                    "keywords": [
                        "Luxterna License",
                        "Spark Therapeutics",
                        "Outside US"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Anoro Ellipta May Boost GlaxoSmithKline’s Respiratory Franchise Revenues",
                "features": {
                    "keywords": [
                        "Anoro Ellipta",
                        "GlaxoSmithKline",
                        "Respiratory Franchise"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment",
                "features": {
                    "keywords": [
                        "Leadership",
                        "Segment",
                        "GlaxoSmithKline"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "What to Expect for Novartis’s Subsidiary Alcon in 2018",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Alcon",
                        "Expectations"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "GlaxoSmithKline Has Developed a Broad Respiratory Portfolio",
                "features": {
                    "keywords": [
                        "Broad Respiratory Portfolio",
                        "GlaxoSmithKline"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Taking Stock of Radius Health’s Financial Performance",
                "features": {
                    "keywords": [
                        "Radius Health",
                        "Financial Performance"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "How Is Novartis’s Subsidiary Sandoz Positioned for 2018?",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Sandoz",
                        "Positioned"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "generic drugs"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "The Swiss Stock Market Recovered Some Lost Ground",
                "features": {
                    "keywords": [
                        "Swiss Stock Market",
                        "Recovered",
                        "Lost Ground"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "financial markets"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}